Immediate Impact
53 standout
Citing Papers
Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
2025 Standout
PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment
2024 Standout
Works of Geraldine Ferron‐Brady being referenced
Exposure–Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma
2021
Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma
2014
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Geraldine Ferron‐Brady | 199 | 311 | 71 | 195 | 32 | 548 | |
| T Ishihara | 93 | 204 | 26 | 93 | 33 | 524 | |
| Sherry Yang | 29 | 209 | 63 | 302 | 29 | 632 | |
| E. Stathopoulos | 34 | 166 | 29 | 331 | 40 | 615 | |
| William Gibson | 38 | 313 | 12 | 237 | 22 | 642 | |
| Antonette E. Leon | 23 | 285 | 73 | 251 | 24 | 637 | |
| Nadja Kopp | 180 | 382 | 12 | 162 | 21 | 632 | |
| Gian Antonio Da Prada | 265 | 88 | 12 | 250 | 31 | 554 | |
| A. Bamias | 102 | 204 | 34 | 222 | 27 | 549 | |
| R. Mione | 15 | 279 | 148 | 278 | 45 | 620 | |
| Mary Collier | 40 | 228 | 16 | 330 | 24 | 552 |
All Works
Login with ORCID to disown or claim papers
Loading papers...